-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4057 New Insights into Hematopoietic Redefinition and New Paradigms in Hematopoietic Hierarchy Roadmap

Program: Oral and Poster Abstracts
Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
Monday, December 11, 2023, 6:00 PM-8:00 PM

Lipeng Chen1*, Qing Sun, PHD2*, Jihao Zhou, MD3*, Guoqiang Li3*, Qijun Huang1*, Xiao Qiu3*, Jiahe Zhang3*, Chun Feng3*, Lina Hu3* and Yongjian Yue, PhD1*

1Shenzhen Institute Of Respiratory Disease, Shenzhen People’s Hospital, Shenzhen, China
2Shenzhen Zhongshan Urology Hospital, Shenzhen, China
3Department of Hematology, Shenzhen People’s Hospital, Shenzhen, China

The definition of hematopoietic progenitor cells (HPCs) has not been standardized. Surface markers are insufficient to capture the entire differentiation stages of progenitor cells and reflect the dynamic differentiation mechanisms underlying hematopoiesis. Deciphering the hematopoiesis mechanism that underlies progenitor cells definition and fate decision are critical to understanding fundamental questions of hematopoietic lineage commitment.

Here, we redefined the entire spectrum of adult hematopoietic progenitors, and recovered the critical transcript factors (TFs) in lineages fate decision, and reaffirmed the lineage commitment model of HPCs by a comprehensive transcriptome. The progenitor lineages were accurately redefined with unique makers and transcription factors by unsupervised dimensionality reduction and clustering, which subverted the conventional definition of HPCs(Table 1). The expression characteristics of TFs, such as GATA1, KLF1, PRDM1, and MAFB, presented enormous capacity to define the entire spectrum of HPCs.

The transcriptional atlas showed that original hematopoietic progenitors were simultaneously primed into lymphoid, neutrophils, and megakaryocytic–erythroid progenitor cell types in the initial differentiation stage and thereafter matured into different hematopoietic lineages (Figure 1). The common intermediate progenitor stage was not observed among myeloid lineages, indicating the absence of a common myeloid progenitor during the lineage commitment. Our transcriptional atlas revealed the major fate decision factors in each branch among hematopoietic hierarchy formation (Table 1). Several fate decision factors were identified, including GATA2, TESPA1, and MYB of myeloid progenitors and HOXA9, HOPX, and TSC22D1 of lymphoid progenitors. Through the sequential activation/deactivation of TFs, synergism with key receptor genes, and signal activation, the original progenitor cells were primed and differentiated into various progenitors. The expression and activation characteristics of fate decision TFs faithfully reflect the mechanisms underlying hematopoietic lineage commitment.

A hematopoietic hierarchy roadmap was reaffirmed. Our reaffirmed hematopoietic hierarchy validated that the megakaryocytic–erythroid lineage process is continuous, while the lymphoid lineage process is more likely a discrete stepwise progression with distinct lineage-committed populations during hematopoiesis, opening a new perspective on hematopoiesis (Figure 1). Our study revealed that the original progenitors of basophils, eosinophils, and neutrophils differed. Plasma progenitor cells were first identified and defined, and the rearrangements of IGHV, IGKV, and IGLV genes were already existed and occurred during the progenitor state of plasma cells.

In summary, our transcriptional atlas of HPCs provides an accurate definition, hierarchy, and biological insights into hematopoiesis and lineage commitment. Our study opens up numerous possibilities for precise and controlled progenitor cell differentiation, facilitating research development in regenerative medicine and disease treatment.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH